An experimental drug called, veliparib, is being studied for treatment of patients with squamous NSCLC. This drug is a "PARP" inhibitor and may be used with chemotherapy or radiation to help improve efficacy. Although it's too early to tell if this drug will be FDA-approved, the possibility of having another treatment option is exciting news. A press release can be found here: biospace.com/News/abbvie-re...
FDA grants orphan drug status to an ex... - Lung Cancer Support
FDA grants orphan drug status to an experimental drug for squamous NSCLC
Written by
MFH_Advocate
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression
full release here: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezo
First Targeted Adjuvant Therapy for EGFR Non Small Cell Lung Cancer (stage IB-IIIA)
the full FDA press release:...
To be, or not to be...NED. That is the question -William Shakespeare and me 😂
before rushing back into treatment. Treatment this time would be the trial drug (it’s no longer a...
Pet Scan results are back
The suggested course of treatment is Radiotherapy, problem is it is the treatment which will scar a...
Mom just diagnosed Stage IV
Stage IV NSCLC and begins chemo (Carboplatin + Alimta) on 12/28. She is a non-smoker and the news,...